Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Automated Apnoea Detection in Preterms on Non-invasive Ventilation

25. august 2026 oppdatert av: King's College Hospital NHS Trust

Prospective Observational Study of Automated Apnoea Detection in Preterm Infants Receiving Non-invasive Respiratory Support

The aim of this study is to monitor the frequency of apnoeas (pauses in breathing) on various methods of non-invasive respiratory support that are detected by an automated machine-learning (ML) model based on diaphragmatic electromyography (dEMG), in infants born at less than 32 weeks of gestation.

Our hypothesis is that the ML algorithm will improve identification of apnoeic episodes and their classification to central or obstructive.

The study will measure outcomes including the number of apnoeic episodes during the monitoring period, their classification to central and obstructive apnoeas and the predictive ability of the machine-learning algorithm to correctly identify and classify these episodes compared to those documented in nursing charts. Correct classification of apnoeic episodes may help identify underlying causes that require specific intervention.

Studieoversikt

Status

Har ikke rekruttert ennå

Detaljert beskrivelse

When the clinical team identifies an infant is eligible for enrolment to the study and following verbal assent of the attending neonatal consultant, a member of clinical staff will initially approach the parents/ legal guardians of eligible infants and if they agree, a researcher. The parents will be provided with an information sheet about the study. The researchers will answer questions and respond to any concerns in a face-to-face meeting. Written informed consent will be obtained.

Electrical activity of the diaphragm, airway pressure, flow and peripheral oxygen saturation levels will be recorded for a duration of eight hours. Transcutaneous diaphragm EMG (sEMG) will be monitored using three surface electrodes (3M Red Dot Foam monitoring electrode 2228, 3M, United Kingdom) that are placed on the infant's abdomen and sternum. The electrodes are connected to a small battery-operated measuring device (SERA, DEMCON; Makawi Medical Systems, the Netherlands) that amplifies and pre-processes the signals received from the electrodes. The pre-processed signals are sent via a Bluetooth connection to a receiving unit that performs higher level processing to derive the EMG signal and other measurements. These results are communicated via a wired connection to a bedside computer running SERA Graphical User Interface (GUI) software.

Airway pressure and flow signals will be measured by a flow sensor and pressure tube (Sensirion AG, Stäfa, Switzerland) that will be placed between the exit of the SLE6000/ SLE6000N ventilators (Inspiration Healthcare, Croydon, UK) and the tubing that is attached to the patient. This will ensure pressure and flow data are recorded simultaneously with the sEMG signal. These data will also be fed to the SERA measuring device.

An SpO2 cable (SLE uSpO2, Inspiration Healthcare, Croydon, UK) will be connected to the patient and the ventilator for continuous (second by second) recording of SpO2 levels. These data will be time synced using post processing.

Participants will also be connected to the standard bedside monitor (Phillips Intellivue MX750) for the whole duration of the study.

Surface EMG, pressure, flow and SpO2 data will be synchronised. Two researchers will identify all apnoeic episodes and classify them as central, obstructive or noise.

The ML algorithm will also be used to identify and classify apnoeic episodes that occurred during the study duration.

Comparisons will be made between the apnoeic episodes identified the researchers, the ML algorithm and the nursing staff electronic patient records. These records include classification of an episode as apnoea or desaturation or bradycardia, its duration and any actions taken.

Studietype

Observasjonsmessig

Registrering (Antatt)

30

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Barn

Tar imot friske frivillige

Nei

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Infants admitted and cared for at the Neonatal Intensive Care Unit at King's College Hospital

Beskrivelse

Inclusion Criteria:

Preterm infants <32 weeks of gestation at birth and up to 36 weeks postmenstrual age, on non-invasive respiratory support including:

  • non-invasive positive pressure ventilation (NIPPV)
  • nasal continuous positive airway pressure (CPAP)
  • heated humidified high flow nasal cannula (HHFNC) oxygen, either as primary or post extubation respiratory support.

Exclusion Criteria:

  • Infants born above 32 weeks of gestation.
  • Infants with known major congenital abnormalities.
  • Infants above 36 weeks postmenstrual age (PMA).
  • Non-English speakers.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
Number of apnoeic episodes correctly identified by the automated machine learning model
Tidsramme: From enrollment to the end of monitoring at eight hours
From enrollment to the end of monitoring at eight hours

Sekundære resultatmål

Resultatmål
Tidsramme
The proportion of apnoeas correctly classified as central or obstructive by the automated machine learning model
Tidsramme: From enrollment to the end of monitoring at eight hours
From enrollment to the end of monitoring at eight hours

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Anne Greenough, Professor, King's College Hospital NHS Trust

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

7. september 2026

Primær fullføring (Antatt)

27. juli 2027

Studiet fullført (Antatt)

27. juli 2027

Datoer for studieregistrering

Først innsendt

25. august 2026

Først innsendt som oppfylte QC-kriteriene

25. august 2026

Først lagt ut (Faktiske)

31. august 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

31. august 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

25. august 2026

Sist bekreftet

1. august 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere